Ascentage Pharma Group International furnishes SEC filings as a foreign private issuer reporting under Form 6-K and indicating annual reporting on Form 20-F. The filings document press releases and Hong Kong Stock Exchange announcements for annual results, oncology pipeline updates, clinical and preclinical presentation materials, and changes in corporate administration.
The company’s filing record also includes Hong Kong annual report and environmental, social and governance materials, annual general meeting notices, proxy forms, director re-election matters, general mandates to issue or repurchase shares, and supplemental equity-incentive grant proposals under its RSU and post-IPO share option schemes.
ASCENTAGE PHARMA GROUP INTERNATIONAL filed an initial insider ownership report for Veet Misra, who serves as Chief Financial Officer. The available data lists Misra as the sole reporting person and shows no insider transactions or derivative positions in the excerpted information.
ASCENTAGE PHARMA GROUP INTERNATIONAL filed an amended insider ownership report for Chief Accounting Officer Jin Cao. The filing shows direct ownership of 5,400 Ordinary Shares, which had been inadvertently omitted previously, and 12,883 restricted stock units (RSUs).
Each RSU represents a contingent right to receive one Ordinary Share upon vesting. The RSUs vest in four equal installments on November 26 of 2026, 2027, 2028 and 2029, and do not have an expiration date.
Ascentage Pharma Group International filed a report describing its participation in the AACR 2026 Annual Meeting, where it is presenting four preclinical poster studies on combination cancer therapies. The work features three drug candidates: olverembatinib, APG-2449, and APG-5918 across hematologic malignancies and solid tumors.
The studies explore olverembatinib beyond its approved use in China for chronic myeloid leukemia, including endometrial carcinoma and mantle cell lymphoma, as well as APG-2449 in BRAF V600E-mutant tumors and APG-5918 in small-cell lung cancer. These preclinical data are intended to help guide ongoing and planned global registrational trials in multiple cancer indications.
Ascentage Pharma Group International reported the initial equity holdings of Chief Accounting Officer Jin Cao. The filing shows 12,883 restricted stock units (RSUs), each representing a contingent right to receive one Ordinary Share upon vesting.
The RSUs vest in four equal installments on November 26 of 2026, 2027, 2028 and 2029 and have no expiration date. The position is held directly and reflects equity-based compensation rather than an open-market share purchase or sale.
Ascentage Pharma Group International has changed its principal place of business in Hong Kong. Effective April 1, 2026, the address is now Unit 906, 9/F., Haleson Building, 1 Jubilee Street, Central, Hong Kong.
The change is reported on a Form 6-K, which furnishes the related Hong Kong announcement and is signed by Chief Executive Officer Dr. Dajun Yang.
Ascentage Pharma reported unaudited 2025 results showing strong product momentum but much heavier losses. Revenue was RMB574.1 million (US$82.1 million), down from RMB980.7 million in 2024 because the prior year included RMB678.4 million of one‑off intellectual property income. Core drug sales improved: Olverembatinib revenue in China rose 80.6% to RMB435.3 million (US$62.2 million), and newly launched Lisaftoclax contributed RMB70.6 million (US$10.1 million) in its first months on the market. Investment in growth was substantial, with selling and distribution expenses up 80.4% and research and development expenses up 20.1% to RMB1,137.4 million (US$162.7 million). As a result, net loss widened sharply to RMB1,243.0 million (US$177.7 million) from RMB405.7 million. Liquidity strengthened, as cash and bank balances nearly doubled to RMB2,470.1 million (US$353.2 million), funded by a U.S. Nasdaq IPO raising US$132.5 million and a Hong Kong follow‑on offering raising US$190.1 million. Clinically, the company advanced nine registrational trials across Olverembatinib, Lisaftoclax and APG‑2449 and secured FDA and EMA clearances for additional Phase III studies, while APG‑3288, a BTK degrader, received IND clearances in the U.S. and China.
ASCENTAGE PHARMA GROUP INTERNATIONAL Chief Medical Officer Yifan Zhai filed an initial ownership report listing existing holdings, rather than new trades. The filing shows options and restricted share units over ordinary shares, vesting in four equal parts on each of 11/26/2026, 2027, 2028 and 2029, plus direct and indirect ordinary share positions held through a trust, spouse and HealthQuest Pharma Limited.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Wei Ren has filed an initial ownership report on Form 3, detailing current equity holdings in the company. The filing shows stock options over 18,850 Ordinary Shares at an exercise price of $8.1400 per share, expiring on November 26, 2035. These options vest in twelve equal monthly tranches starting on November 26, 2025.
Ren also holds restricted share units (RSUs) linked to 28,850 Ordinary Shares, which vest in four equal increments on each of November 26, 2026, 2027, 2028 and 2029. In addition, the filing lists direct ownership of 8,964 Ordinary Shares as of the reported date, providing a clear picture of Ren’s existing economic stake and unvested awards.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Ye Changqing filed an amended initial ownership report that corrects and clarifies his equity holdings. The filing shows options over 18,850 Ordinary Shares at an exercise price of $8.14 expiring on November 26, 2035, 28,850 restricted share units that vest in four equal annual installments from November 26, 2026 through 2029, and 8,964 Ordinary Shares held directly. Footnotes explain that the numbers of Ordinary Shares, share options, and vesting schedules were inadvertently reported incorrectly in the original submission.
ASCENTAGE PHARMA GROUP INTERNATIONAL filed an amended insider ownership report for director Debra Yu, updating previously reported equity awards. The amendment shows stock options over 17,965 Ordinary Shares with an exercise price of 8.1400 per share and an expiration date of November 26, 2035. These options vest in twelve equal monthly tranches on the 26th of each month starting November 26, 2025. It also reports 27,965 restricted share units, each representing one Ordinary Share that vests in four equal installments on November 26 of 2026, 2027, 2028 and 2029. A footnote states the number of share options and/or vesting was inadvertently reported incorrectly in the original submission.